|
Mr. Weaver currently holds the position of chief financial officer for TALYST a privately-held Bellevue WA healthcare company engaged in providing software solutions for pharmacy management. Prior to joining Talyst Weaver held the position of senior vice president and chief financial officer of Sirna Therapeutics (NASDAQ: RNAI) a San Francisco biotechnology company which was acquired by Merck in 2006. He was formerly chief financial officer of Nastech Pharmaceuticals (NASDAQ: NSTK) a Bothell Wash. drug delivery company and prior to that Weaver served as chief financial officer of Ilex Oncology (NASDAQ:ILXO) a biopharmaceutical company.
Earlier in his career he held several senior financial management positions including chief financial officer of Prism Technologies a medical device company and chief financial officer of a division of Fidelity Capital. Previously Mr. Weaver held increasingly senior positions with Fidelity Capital and Harte-Hanks (NYSE: HHS) in the publishing industry. Mr. Weaver began his career with Arthur Andersen LLP. | 